Ann Arbor, Michigan, Sept 15th, 2015: TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, has presented on various topics at the Cutting Edge/Drug Discovery & Development in Michigan Symposium September 9th and 10th.
Eric Simon, PhD presented on the "Development of an LC-MS Assay for Measurement of of Intracellular Concentrations of Cidofovir Prodrug USC-505 and its Metabolites". Shyamala Ganesan, PhD presented on "Improved Intracellular Concentrations of Cidofovir Diphosphate Using an Oral Prodrug Approach". Andrew Hertig, MBA, presented on "The Preclinical Accelerator: A New Model for Drug Development".
Presentations are available for viewing here:
About TSRL, Inc.
TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734-663-4233 x236, email@example.com.